Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Our data IS spectacular. Make no mistake.
Once again...
The question was (paraphrasing):
“Do you need to raise money through either dilution or obtaining a partner?”
Missling’s answer (paraphrasing):
“No. We have enough cash on hand now to fund all the planned trials including the RTT, PD, and 2/3 AD.”
This is the abridged and paraphrased version. I already posted an exact transcript. I am taking no liberties with my paraphrase or transcript. He said it. It is documented in no uncertain terms. It cannot be argued.
Again... comprehension is a necessary and important quality investors should learn to develop.
Here is the exact question asked:
“What are going to be the costs projected for the next phase of trials and is the company well-capitalized to do that? Do you need to go out to the market to raise more funds or should we be expecting a partner with this good news that you have so far?”
Here are Missling’s exact words in response:
“So, the finances are mentioned in the last slide. We have two years of cash that includes all the budget for the studies we have announced we will entertain. Which is the Rett Syndrome study, which is the Parkinson’s Study, and which is the Alzheimer’s phase 2/3 study. So we are well-funded. We right now don’t need to raise any funds.”
He says we do not need a partner at this time. He says we don’t need to dilute. And he says we have enough cash on hand right now to fully fund the projected budgets for all three trials.
That is what he said, like it or not. Thems the words.
Now... you may doubt that what he says is going to work out as he expects, but he said what he said and you can’t change it.
Bottom line...
If you think any of the remarks in the conference call yesterday were anything but unbridled enthusiasm for what all three speakers consider unblemished and completely positive results... then you really have a serious problem with comprehension.
Reality time: three trials starting before year’s end. Phase 2/3 start in AD will cause huge surge in pps before 12/31/17. That’s the breaks ladies and gentlemen.
Complete confirmation yesterday that all of the company’s planned and stated goals for this year are still on track, completely paid for by current cash holdings of AVXL, and results/patients in 2a trial are CONTINUING TO IMPROVE even now.
Just a slight adjustment to your transcript,,,
“Further, it’s important to note that the data that’s showing (now I’m talking about the statistical thing) to this approach actually is benefitting patients. They’re actually improving.”
He is talking about the statistical analysis that the Ariana CEO had just summarized. What he is saying is that the statistics provided by Ariana show improvement. And he goes on to say that this has never happened. Not even with currently approved and prescribed drugs.
THIS IS UNPRECEDENTED. If these results continue into the 2/3 study it will be one of the biggest bombshells in biotech’s history.
I would guess that the reason for the conference call today is because a PR about start of RTT is coming before 11/4. Company wanted to get PK/PD out first per prior statements.
No. He stated that they have sufficient cash on hand. Not that they have a partner with sufficient cash.
Need to get past this notion of a mystery partner waiting in the wings.
LOL!
Obvious lies.
Beware the Short in Long’s coverings.
Short squeeze coming soon. Probably gap up about 4 or 5 bucks before Shorts know what happened.
I’ll be ROTFL!!!
I’d estimate that we should see at least $15 before this year’s end.
375 may have been broken up in two or several smaller blocks. That occurred on one of his previous 375 share purchases.
You're right and wrong at the same time.
Right in the content of your reply. Wrong in that you missed the facetiousness with which my post was brimming.
I don't think we will get any trials started before 11/4 CTAD conference.
Per Missling, PK/PK will come first.
I think we will get noticed before the RTT trial is complete.
Going to be making a lot of noise in the next few weeks!
99.6% failure rate???
Sounds like we are due for a winner! Law of averages...
Oh... you're way behind.
http://www.rettsyndrometrial.com/
I would be shocked if BIIB hasn't already determined the answer to any lingering 2-73/MS related questions on their own. Plenty of time has passed. If they are still engaged with AVXL then the the future is going to be great for them and AVXL.
From the PR on 2/19/16:
"Studies to determine the relative roles of S-1R agonism, NMDAR antagonism and muscarinic activities are objectives for future studies. ANAVEX2-73 and DM are small molecules that enter the central nervous system and thus have potential to provide protection of OL in MS."
I'd expect the upcoming presentation to answer the above question.
Here's a link to the original poster:
https://actrims.confex.com/actrims/2016/meetingapp.cgi/Paper/1218
HaHaHa!
You're a riot!!
When they presented their original findings in early 2016 (I'd have to check exact date) they said that there would be additional research released at later conferences. This is apparently that further research. It's is all tied together with their original testing.
There have been additional trials. Wayne State is presenting further findings this month. BIIB has been continuing confirmatory testing since last September.
$60-$70/share offer for AD is so low. Not worth selling at that price at all, especially when you factor in looming RTT approval possible within a year.
If RTT gets approved (not even counting epilepsy) it should go to $60-$70. Not based on just RTT sales, but factoring in speculation based on positive results and healthy revenue stream.
I don't think we will see that for a couple reasons.
It is a short term study to begin with, followed by the option for anyone in the trial (including placebo patients) to continue with 2-73 treatment if they desire.
The trial protocols are already decided and did not mention any crossing over.
You are incorrect. Try to catch up.
Shouldn't hear news like that till after CTAD in November, per Missling.
I think they just wanted to make the chart less "busy" and easier to read. It doesn't need to be an exhaustive tome.
Obviously, all of the dropped indications have been out-licensed.
(tongue firmly in cheek)
BIIB would be partners with AVXL. Both would be in control together. And AVXL would absolutely have the right to show the phrase MS on a pipeline chart showing that their drug is being tested on MS.
Actually... the catalysts list showed that the licensing goal was "ongoing" as in, continuing...still in progress.
The list of catalysts is in chronological order based on predictions and plans of the company. Since attempts/plans for licensing is "ongoing" and has been for a while they would have to list it at the end since they can't be sure where in the timeline it will/could fall.
Why would they remove the MS indication from the chart over a licensing deal?? That makes no sense.
The chart is basically an ad for 2-73. It is getting the info/name out there for investors. If you license 2-73 for MS you are still going to advertise it because it builds the foundation for its worth to potential investors. Plus you are hopefully going to see income from MS prescriptions for AVXL's shareholders once approved for MS.
Licensing it does not mean you have to act like it doesn't exist anymore. In fact, you would perhaps feature it more prominently since it is the one indication that a big player has openly endorsed. When negotiating its licensing you would not be required to pull down every mention of it in relation to MS. It's a great confidence booster for all the other indications for potential investors.
I tend to think that the "MS chart mystery" bodes good things to come. But I'm only slightly inclined in that direction. Say... 60/40 to the good side. I'm not jumping up and down yet because there is a real possibility that it is not good. Don't want to get high hopes (again) and be disappointed.
One thing is certain though... starting in November we are going to see a parade of good news that should push us up and up. May even see upward speculation surge in October in anticipation.
Pure speculation. You offer one possible conclusion, however it is far from being a slam dunk.
One huge problem with this theory is that we haven't seen any leaks or resulting price spikes. Very unlikely to have no such leaks with a deal of that magnitude, especially with a very large party involved like BIIB.
I Agree totally.
WoW! Today is the anniversary of the MTA. Doesn't time just fly!
My point is that they do not appear to be presenting any new data. Everyone wants to jump 50 spaces ahead in their assumptions and before long we're talking like a licensing deal has already happened.
It would behoove everyone to curb their enthusiasm and stop having delusions about a BIIB deal that isn't real.
Maybe I'll be proved wrong (I wholeheartedly hope so), but in the meantime wouldn't it be prudent to not count your licensing deals before they hatch?
So, nothing new since that was already presented, right?
If there is an MS licensing deal, why would anyone be allowed to present a sales pitch for 2-73 in relation to MS?
If they licensed MS to BIIB then why would they be presenting MS at a conference in a couple weeks?
It will be at CTAD in November. Should get a nice price swell till then in anticipation of huge Nov/Dec.